Gastroenterology Market Synopsis:
\nGastroenterology Market Size Was Valued at USD 34.6 Billion in 2023, and is Projected to Reach USD 60.5 Billion by 2032, Growing at a CAGR of 6.4% From 2024-2032.
\nThe Gastroenterology Market is a segment of the overall market of healthcare services, which concentrates on the assessment, Prevention, and control of health disorders of the gastrointestinal system. This include those affecting the esophagus, stomach, small and big intestines, liver, pancreatic and the gall bladder. It consists of drugs, equipment and diagnostic services as well as treatment services oriented towards chronic and acute gastrointestinal conditions, including, Crohn\u2019s disease, ulcerative colitis, IBS, GERD and liver diseases.
\nThe gastroenterology market has reported growth over the years due to the increasing incidence of gastrointestinal diseases and growth in the global geriatric population, which is inclined to GI diseases. Recent developments in diagnostic procedures and the increase in new and sophisticated methods of performing therapeutical interventions without the need for large operations have also contributed to market growth. Moreover, changes in life customs for unhealthy diets, more alcohol consumption, and obesity levels have caused the development of new GI diseases requiring better treatment or control. New product development in the area of biologics and biosimilars is delivering better efficacy in the patient population of chronic gastrointestinal disorders, thus driving the pharmaceutical segment of the gastroenterology market.
\nIncreased interest in alimentary tract procedures and equipment: there is now renewed concern with early intervention and prevention. This has promoted the utilisation of endoscopy and colonoscopy more so because of the rising healthcare cost in both developed and the developing world. Similarly, the growing number of joint ventures between the healthcare companies and the pharmaceutical industries to bring in the new therapeutic products is further driving the growth of gastroenterology market. Promotions in understanding digestive health and diseases coupled with more funding for research and development has made the environment ideal for growth in the market. <\/p>\n
Gastroenterology Market Trend Analysis:
\nPersonalized Medicine Revolutionizing GI Treatment<\/p>\n
Another interesting trend that becomes increasingly prominent within the gastroenterology market is that of prescript personalization. This approach means that treatment plans are developed based on an individual\u2019s DNA making the therapies provided for the GI conditions more efficient. Thanks to genomics and biomarkers, terminology professionals are in a position to definitely identify peculiarities of the genome that are linked to gastrointestinal disorders \u2013 this information becomes valuable for both diagnostics and treatment. More and more patients with IBD and other chronic gastrointestinal conditions are opting for personalized medicines that include biologics as well as small molecules. The future development of such agents should reshape current and future gastroenterologic treatment paradigms for the better of patient care experiences and, likely, the direct reduction of side effects.
\nGrowing Demand for Non-Invasive Diagnostics<\/p>\n
The increasing popularity of other diagnostic procedures, which does not mean hospitalization is a good chance in the gastroenterology market. The conventional tissue-probing procedures including biopsies and colonoscopies are giving way to minimally invasive techniques including capsule endoscopy, colonoscopies, and comprehensive imaging purposes. These methods also present quicker and more accurate diagnose with little uncomfortable to the patients. Since patients are going for non-surgical solutions as much as possible, any firm that does the research to produce and sell better diagnostic products will drive a lot of traffic. Further, with the enhancement of applications of AI and machine learning, diagnostic accuracy is projected to receive a boost, this is a promising market area for the players.
\nGastroenterology Market Segment Analysis:
\nGastroenterology Market is Segmented on the basis of type, Route of Administration, Application, and Region
\nBy Type, Branded segment is expected to dominate the market during the forecast period<\/p>\n
Market of gastroenterology is likely to be dominated by branded segment in the forecast period. This has been due to the increased effectiveness couple with safety of branded products mainly in persistent and complicated GI disorders. The targeted mechanism of action of branded biologics especially in the treatment of IBD, Crohn\u2019s disease and ulcerative colitis makes them the most preferred. Moreover, branded drugs attract a high price because of patent protection, a fact, which, combined with sustainable reimbursement in developed markets, contributes to the dominance of the segment. Nevertheless, generics and biosimilars attract the increased attention of healthcare providers and thus do not threat the position of branded drugs which has the strong brand identification.
\nBy Route of Administration, Oral segment expected to held the largest share <\/p>\n
It is believed that the oral segment will be largest portion of the gastroenterology market. A major factor is that oral drug administration continues to receive the highest preference among patients and health care practitioners because of its ease, noninvasive nature, and compliance. The bulk of gastroenterology therapy, especially for hard-to-cure ailments such as GERD, IBD, and IBS, is oral, which makes this segment by far the largest. Also, continued research and development of the oral drug delivery system, including controlled release products and enteric coatings, continue to improve the potential of drugs administered orally in the management of GI diseases. Due to relatively lower prices acts and oral treatments are well preferred by majority of patients world over hence contributing to their popularity in the market.
\nGastroenterology Market Regional Insights:
\nNorth America is Expected to Dominate the Market Over the Forecast period <\/p>\n
In 2023, North America will rule the global market of gastroenterology product and services as it has largest market share in the market due to advance healthcare facilities and high incidences of GI diseases. As of today, many countries of this region can be called post-industrial in terms of the development of their health care, along with access to up-to-date diagnostics and treatment methods that allow for focusing on the development of gastroenterology. <\/p>\n
Furthermore, high healthcare costs, good government support to R&D, and availability of leading producer companies augur well for the region. It is predicted that the North American region enjoys a market share of about 35-40% of the total gastroenterology market size in 2023. The prevalance of biologics, enhancing diagnostic techniques, and a rising geriatric populace are acting as drivers to the evolution of this market in this realm.
\nActive Key Players in the Gastroenterology Market:<\/p>\n
AbbVie (USA)<\/p>\n
Amgen (USA)<\/p>\n
AstraZeneca (UK)<\/p>\n
Bayer AG (Germany)<\/p>\n
Boehringer Ingelheim (Germany)<\/p>\n
Bristol-Myers Squibb (USA)<\/p>\n
Eli Lilly and Company (USA)<\/p>\n
F. Hoffmann-La Roche (Switzerland)<\/p>\n
GlaxoSmithKline (UK)<\/p>\n
Johnson & Johnson (USA)<\/p>\n
Merck & Co. (USA)<\/p>\n
Novartis (Switzerland)<\/p>\n
Pfizer (USA)<\/p>\n
Sanofi (France)<\/p>\n
Takeda Pharmaceutical (Japan)<\/p>\n
Other Active Players<\/p>\n","protected":false},"excerpt":{"rendered":"
The Gastroenterology Market is a segment of the overall market of healthcare services, which concentrates on the assessment, Prevention, and control of health disorders of the gastrointestinal system.<\/p>\n","protected":false},"featured_media":24222,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[194],"product_tag":[],"class_list":["post-27031","product","type-product","status-publish","has-post-thumbnail","product_cat-healthcare-life-sciences","first","instock","virtual","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n